Gene therapy for pulmonary diseases

Area of Science:

• Medical Genetics
• Pulmonary Medicine
• Gene Therapy

Background:

• Alpha 1-antitrypsin (alpha 1AT) deficiency and cystic fibrosis (CF) are common fatal hereditary lung disorders.
• These conditions serve as models for emphysema and chronic bronchitis, respectively.
• Gene therapy presents a potential therapeutic avenue for these diseases.

Purpose of the Study:

• To explore the feasibility of gene therapy for alpha 1-antitrypsin deficiency and cystic fibrosis.
• To evaluate the use of recombinant replication-deficient adenovirus vectors for in vivo gene delivery.

Main Methods:

• In vitro and in vivo experimental animal studies were conducted.
• Adenovirus vectors carrying normal gene copies were administered.
• Delivery routes were investigated based on therapeutic targets (e.g., lung, liver, vascular endothelium, epithelial cells).

Main Results:

• The feasibility of in vivo gene therapy approaches was demonstrated.
• Adenovirus vectors successfully delivered therapeutic genes in experimental models.
• Targeted delivery to specific cell types was shown to be achievable.

Conclusions:

• Gene therapy using adenovirus vectors is a viable strategy for treating alpha 1-antitrypsin deficiency and cystic fibrosis.
• In vivo administration of recombinant adenovirus vectors holds promise for correcting these hereditary lung diseases.